AstraZeneca

News

AZ researches kidney and lung drugs with BenevolentAI

AstraZeneca has become the latest big pharma to jump on the artificial intelligence R&D bandwagon, penning a deal with the UK’s BenevolentAI to find new kidney and lung drugs.<

News

AstraZeneca revival continues as new cancer drugs gallop ahe...

AstraZeneca’s revival has continued with a third successive quarter of growth, as sales of new drugs for cancer and lung diseases outperformed the market’s expectations.

News

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app

News

AZ's Fasenra also works in rare organ damage diseases

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown.

News

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for an antibody-drug conjugate and potential new targeted cancer medicine,

News

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

AstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC), with the drug made available via the Cancer Drugs Fund for now.

AZ researches kidney and lung drugs with BenevolentAI

AstraZeneca revival continues as new cancer drugs gallop ahe...

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

AZ's Fasenra also works in rare organ damage diseases

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks